P. Dull

发表

Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials

T. Vesikari, D. Toneatto, S. Esposito, 2013, The Lancet.

A response adaptive randomization platform trial for efficient evaluation of Ebola virus treatments: A model for pandemic response

Scott M Berry, C. Woods, M. McClain, 2016, Clinical trials.

Antibody persistence 5 years after vaccination at 2 to 10 years of age with Quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccination.

S. Block, P. Dull, P. Keshavan, 2015, Vaccine.

Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers.

T. Odrljin, P. Dull, Miguel W. Tregnaghi, 2014, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Safety and Immunogenicity of a Novel Quadrivalent Meningococcal CRM-conjugate Vaccine Given Concomitantly With Routine Vaccinations in Infants

T. Odrljin, K. Reisinger, C. Gill, 2012, The Pediatric infectious disease journal.

A Randomized Trial to Determine the Tolerability and Immunogenicity of a Quadrivalent Meningococcal Glycoconjugate Vaccine in Healthy Adolescents

K. Reisinger, R. Jacobson, L. Jackson, 2009, The Pediatric infectious disease journal.

Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.

K. Reisinger, L. Jackson, R. Baxter, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers

S. Halperin, F. Diaz-Mitoma, P. Dull, 2010, European Journal of Clinical Microbiology & Infectious Diseases.

Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages.

R. Rappuoli, P. Dull, M. Bröker, 2009, Vaccine.

Quadrivalent Meningococcal Vaccination of Adults: Phase III Comparison of an Investigational Conjugate Vaccine, MenACWY-CRM, with the Licensed Vaccine, Menactra

K. Reisinger, S. Block, R. Baxter, 2009, Clinical and Vaccine Immunology.

Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines.

P. Dull, A. Anemona, U. Grunwald, 2010, Vaccine.

Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents

C. Gill, R. Baxter, P. Dull, 2010, Human vaccines.

Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age.

S. Black, N. Klein, P. Dull, 2010, Vaccine.

Safety and immunogenicity of an investigational quadrivalent meningococcal CRM(197) conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America.

P. Dull, P. López, D. Stamboulian, 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults

M. Pizza, L. DeTora, D. Toneatto, 2011, Human vaccines.

Meningococcal serogroup B vaccine (4CMenB): Booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old children.

T. Vesikari, D. Toneatto, R. Prymula, 2015, Vaccine.

A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I)

G. Zuccotti, D. Toneatto, S. Esposito, 2014, Human vaccines & immunotherapeutics.

Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age

T. Odrljin, M. Nissen, T. Nolan, 2014, Human vaccines & immunotherapeutics.

Glycoconjugates: What It Would Take To Master These Well-Known yet Little-Understood Immunogens for Vaccine Development

F. Avci, M. Wacker, J. Hennessey, 2019, mSphere.

Moving fast but going slow: coordination challenges for trials of COVID-19 post-exposure prophylaxis

R. Agrawal, P. Dull, R. Barnabas, 2020, Trials.

Randomized Trial on the Safety, Tolerability, and Immunogenicity of MenACWY-CRM, an Investigational Quadrivalent Meningococcal Glycoconjugate Vaccine, Administered Concomitantly with a Combined Tetanus, Reduced Diphtheria, and Acellular Pertussis Vaccine in Adolescents and Young Adults

R. Gasparini, G. Gabutti, P. Dull, 2010, Clinical and Vaccine Immunology.

Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax.

Sandra K. Martin, R. Ahmed, S. Crotty, 2004, The Journal of infectious diseases.

Specific, Sensitive, and Quantitative Enzyme-Linked Immunosorbent Assay for Human Immunoglobulin G Antibodies to Anthrax Toxin Protective Antigen

Lilah M. Besser, Sandra K. Martin, J. Sejvar, 2002, Emerging infectious diseases.

Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults.

T. Nolan, P. Dull, V. Abitbol, 2015, Vaccine.

Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents

X. Sáez-Llorens, P. Dull, I. Smolenov, 2015, Human vaccines & immunotherapeutics.

accination with a multicomponent meningococcal B vaccine in revention of disease in adolescents and young adults

P. Dull, J. Wassil, erry Nolana, 2015 .

Persistence of antibodies in adolescents 18−24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine

M. Valenzuela, D. Toneatto, P. Dull, 2013, Human vaccines & immunotherapeutics.

Meningococcal vaccine development--from glycoconjugates against MenACWY to proteins against MenB--potential for broad protection against meningococcal disease.

P. Dull, E. McIntosh, 2012, Vaccine.

Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study

M. Valenzuela, D. Toneatto, P. Dull, 2012, The Lancet.

A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program

J. Stoddard, D. Toneatto, P. Dull, 2013, Drugs.

Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?

M. Pizza, M. Giuliani, M. Comanducci, 2013, Vaccine.

A randomized, observer-blind Phase Ib study to identify formulations and vaccine schedules of a trivalent Group B Streptococcus vaccine for use in non-pregnant and pregnant women.

G. Leroux-Roels, P. Dull, K. Slobod, 2016, Vaccine.

Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial

S. Faust, A. Pollard, A. Finn, 2014, The Lancet.

A phase II randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II)

G. Zuccotti, D. Toneatto, S. Esposito, 2014, Human vaccines & immunotherapeutics.

Persistence of Bactericidal Antibodies to 5 Years of Age After Immunization With Serogroup B Meningococcal Vaccines at 6, 8, 12 and 40 Months of Age

A. Pollard, M. Voysey, D. Toneatto, 2014, The Pediatric infectious disease journal.

The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans

D. Toneatto, Kay Vienken, E. Ypma, 2011, Human vaccines.

Immunogenicity and Safety of a Multicomponent Meningococcal Serogroup B Vaccine and a Quadrivalent Meningococcal CRM197 Conjugate Vaccine against Serogroups A, C, W-135, and Y in Adults Who Are at Increased Risk for Occupational Exposure to Meningococcal Isolates

D. Toneatto, A. Kimura, P. Dull, 2010, Clinical and Vaccine Immunology.

A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine.

D. Toneatto, R. Read, J. Findlow, 2017, Vaccine.

Persistence of Meningococcal Antibodies and Response to a Third Dose After a Two-dose Vaccination Series with Investigational MenABCWY Vaccine Formulations in Adolescents

X. Sáez-Llorens, P. Dull, I. Smolenov, 2015, The Pediatric infectious disease journal.

Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age

A. Pollard, M. Voysey, A. Finn, 2016, The Pediatric infectious disease journal.

Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months

Ly-Mee Yu, A. Pollard, D. Toneatto, 2015, Canadian Medical Association Journal.

Bactericidal Antibody Persistence 2 Years After Immunization With 2 Investigational Serogroup B Meningococcal Vaccines at 6, 8 and 12 Months and Immunogenicity of Preschool Booster Doses: A Follow-on Study to a Randomized Clinical Trial

J. Philip, Ly-Mee Yu, A. Pollard, 2013, The Pediatric infectious disease journal.

Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants.

S. Madhi, S. Schrag, P. Heath, 2013, Vaccine.

Maternal Immunization With an Investigational Trivalent Group B Streptococcal Vaccine: A Randomized Controlled Trial

R. Devlieger, S. Halperin, P. Dull, 2016, Obstetrics and gynecology.

Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial.

S. Madhi, P. Dull, K. Slobod, 2016, The Lancet. Infectious diseases.

Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial

S. Madhi, N. French, R. Heyderman, 2016, The Lancet. Infectious diseases.

Neisseria meningitidis serogroup W-135 carriage among US travelers to the 2001 Hajj.

M. Cetron, T. Popović, C. Sacchi, 2005, The Journal of infectious diseases.

Antibody Kinetics and Response to Routine Vaccinations in Infants Born to Women Who Received an Investigational Trivalent Group B Streptococcus Polysaccharide CRM197-Conjugate Vaccine During Pregnancy

S. Madhi, P. Dull, K. Slobod, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial.

A. Pollard, M. Voysey, A. Finn, 2017, Vaccine.

1110Identification of Formulations and Vaccine Schedules of a Trivalent Group B Streptococcus Vaccine for Further Development in Non-pregnant and Pregnant Women

G. Leroux-Roels, P. Dull, K. Slobod, 2014, Open Forum Infectious Diseases.

One-year health assessment of adult survivors of Bacillus anthracis infection.

Dori B. Reissman, D. Ashford, D. Reissman, 2004, JAMA.

Evidence for antibody as a protective correlate for COVID-19 vaccines

A. Fiore-Gartland, P. Gilbert, D. Goldblatt, 2021, Vaccine.

Immunogenicity and Safety of a 3- and 4-dose Vaccination Series of a Meningococcal ACWY Conjugate Vaccine in Infants: Results of a Phase 3b, Randomized, Open-label Trial

S. Block, P. Dull, H. Garfield, 2016, The Pediatric infectious disease journal.

Study Group (2017). Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years

A. Pollard, M. Voysey, P. Dull, 2016 .

Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age.

K. Reisinger, C. Gill, E. Walter, 2010, Vaccine.

Polysaccharide–protein conjugate vaccination induces antibody production but not sustained B-cell memory in the human nasopharyngeal mucosa

R. Heyderman, A. Finn, J. Findlow, 2012, Mucosal Immunology.

Meningococcal disease and vaccines.

P. Dull, N. Rosenstein, 2001, Pediatric annals.

Towards a population-based threshold of protection for COVID-19 vaccines

H. Zar, D. Montefiori, A. Fiore-Gartland, 2021, Vaccine.

Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults.

Ki Bae Hong, T. Odrljin, J. Welsch, 2014, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Etiologies of bacterial meningitis in Bangladesh: results from a hospital-based study.

J. Sejvar, M. Hossain, S. Montgomery, 2009, The American journal of tropical medicine and hygiene.

Antibody Persistence After Primary and Booster Doses of a Quadrivalent Meningococcal Conjugate Vaccine in Adolescents

T. Odrljin, K. Reisinger, S. Block, 2014, The Pediatric infectious disease journal.

Use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in a clinical trial in 3630 infants

T. Vesikari, D. Toneatto, S. Esposito, 2011, Archives of Disease in Childhood.

WHO International Standard for anti-SARS-CoV-2 immunoglobulin

K. Makar, S. Plotkin, G. Mattiuzzo, 2021, The Lancet.

A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial.

S. Block, L. Szenborn, P. Dull, 2015, Vaccine.

Immunogenicity and Immune Memory of a Nonadjuvanted Quadrivalent Meningococcal Glycoconjugate Vaccine in Infants

J. Langley, K. Ford, Ly-Mee Yu, 2009, The Pediatric infectious disease journal.

Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations.

J. Langley, C. Gill, Ly-Mee Yu, 2012, Vaccine.

Seroprevalence and Placental Transmission of Maternal Antibodies Specific for Neisseria meningitidis Serogroups A, C, Y and W135 and Influence of Maternal Antibodies on the Immune Response to a Primary Course of MenACWY-CRM Vaccine in the United Kingdom

D. Kelly, K. Ford, G. Blanchard-Rohner, 2013, The Pediatric infectious disease journal.

Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.

T. Odrljin, K. Reisinger, S. Block, 2014, The Journal of pediatrics.

Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers.

T. Odrljin, N. Klein, P. Dull, 2012, Vaccine.

A Population-Based Threshold of Protection for COVID-19 Vaccines

H. Zar, D. Montefiori, A. Fiore-Gartland, 2021 .

Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.

J. Langley, K. Ford, Ly-Mee Yu, 2008, JAMA.

The etiology of febrile illness in adults presenting to Patan hospital in Kathmandu, Nepal.

C. Woods, D. Murdoch, L. Reller, 2004, The American journal of tropical medicine and hygiene.

High Level of Sequence Diversity in the 16S rRNA Genes of Haemophilus influenzae Isolates Is Useful for Molecular Subtyping

T. Popović, C. Sacchi, L. Mayer, 2005, Journal of Clinical Microbiology.

Country Data for Action: The MenAfriNet Experience in Strengthening Meningitis Surveillance in Africa.

Ryan T Novak, S. Hadler, B. Greenwood, 2019, The Journal of infectious diseases.

Immunogenicity of Alternative Dosing Schedules for HPV Vaccines among Adolescent Girls and Young Women: A Systematic Review and Meta-Analysis

P. Drain, S. Hawes, P. Dull, 2020, Vaccines.

Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.

Ly-Mee Yu, A. Pollard, A. Finn, 2012, JAMA.

Meeting Summary: Global Vaccine and Immunization Research Forum, 2021

B. F. Hall, C. Deal, Kristen A. Earle, 2023, Vaccine.

First Case of Bioterrorism-Related Inhalational Anthrax in the United States, Palm Beach County, Florida, 2001

Tanja Popovic, Richard F. Meyer, J. Sejvar, 2002, Emerging infectious diseases.

ImmunogenicityandTolerabilityofRecombinant SerogroupBMeningococcalVaccineAdministered With or Without Routine Infant Vaccinations According to Different Immunization Schedules A Randomized Controlled Trial

Ly-Mee Yu, A. Finn, D. Toneatto, 2013 .

Prevention of rare diseases: how revolutionary techniques can help vulnerable individuals—the example of serogroup B meningococcal infection

D. Toneatto, P. Dull, J. Wassil, 2015, Therapeutic advances in vaccines.

Clinical features that discriminate inhalational anthrax from other acute respiratory illnesses.

Dori B. Reissman, Dori B Reissman, C. Bridges, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants.

T. Odrljin, N. Chiu, C. Chiu, 2014, Vaccine.

Meeting report: Global vaccine and immunization research forum, 2018

B. F. Hall, P. Dull, M. Friede, 2018, Vaccine.

Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose

Ly-Mee Yu, A. Pollard, D. Toneatto, 2013, Canadian Medical Association Journal.

Antibody Persistence and Response to a Booster Dose of a Quadrivalent Conjugate Vaccine for Meningococcal Disease in Adolescents

T. Odrljin, K. Reisinger, R. Jacobson, 2013, The Pediatric infectious disease journal.

HPV single-dose vaccination: Impact potential, evidence base and further evaluation.

M. Stanley, P. Dull, 2018, Vaccine.

Bacillus anthracis Aerosolization Associated with a Contaminated Mail Sorting Machine

Tanja Popovic, Bill Kournikakis, T. Popović, 2002, Emerging infectious diseases.